The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Sylvester study addresses one of the major mechanisms of pancreatic cancer treatment resistance

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Investigators at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown for the first time that a combination of targeted therapies with immunotherapy addresses a major cause of treatment resistance in pancreatic cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out. 
By Jacquelyn Cobb
Clinical Roundup

Experimental drug doubles one-year survival in pancreatic cancer trial, Northwestern study finds

Patients with pancreatic cancer who received the experimental drug elraglusib, alongside standard chemotherapy, were twice as likely to be alive after one year of treatment, compared to those receiving chemotherapy alone, according to the results of a randomized phase II clinical trial conducted by researchers at Northwestern University. The drug also reduced the risk of death by 38%.
Clinical Roundup

“Lock-and-key” chemistry platform may keep therapeutic drugs inactive until they reach a tumor, Syracuse-led study finds

Many therapeutic molecules used in cancer treatments are highly toxic, often harming healthy tissues and causing significant side effects. This creates a critical need for strategies that localize their toxic activity to tumors. What if cancer drugs could stay dormant until they reach cancer cells? A study by Syracuse University researchers demonstrates a promising chemistry-based strategy that could do just that.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account